US Patent

US8435944 — Method and composition for transdermal drug delivery

Method of Use · Assigned to Acrux DDS Pty Ltd · Expires 2027-09-27 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method and composition for transdermal drug delivery, including at least one physiologically active agent, a volatile solvent, and a viscosity modulating agent.

USPTO Abstract

The invention is directed to a transdermal drug delivery composition which includes at least one physiologically active agent; and at least one volatile solvent; and at least one viscosity modulating agent. The invention extends to methods of administering such a composition to a subject and treatment of subjects using the composition.

Drugs covered by this patent

Androgel (TESTOSTERONE) · Besins Hlthcare

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1390`	—	Androgel

Patent Metadata

Patent number: US8435944
Jurisdiction: US
Classification: Method of Use
Expires: 2027-09-27
Drug substance claim: No
Drug product claim: No
Assignee: Acrux DDS Pty Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.